Research Topics
Species | B S GrahamSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Viruses, dendritic cells and the lungR S Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Respir Res 2:245-9. 2001....
Clinical trials of HIV vaccinesBarney S Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Room 2502, MSC 3017, Bethesda, Maryland 20892 3017, USA
Annu Rev Med 53:207-21. 2002..Future advances will require the discovery of new immunogens that can induce neutralizing antibody, as well as efficacy trial evaluation of regimens optimized for CTL induction...
Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentBarney S Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
Immunol Rev 239:149-66. 2011..These new technologies may allow development of vaccines that can protect against RSV-mediated disease in infants and establish a new immunological paradigm in the host to achieve more durable protection against reinfection...- Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicityBarney S Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 5:e11995. 2010..The peptide mixture was formulated as an emulsion in incomplete Freund's adjuvant (IFA)... - Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccinationB S Graham
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
Mucosal Immunol 3:475-86. 2010..HPV PsV encapsidation of plasmid DNA is a novel strategy for mucosal immunization that could provide new vaccine options for selected mucosal pathogens... - Respiratory syncytial virus immunobiology and pathogenesisBarney S Graham
Viral Pathogenesis Laboratory, National Institutes of Health, Bethesda, Maryland 20892-3017, USA
Virology 297:1-7. 2002 - Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formationLewis H McCurdy
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
J Virol 77:1747-56. 2003..Thus, manipulation of membrane lipid microdomains may lead to alterations in the production of viral filaments and RSV pathogenesis and provide a new pharmacologic target for RSV therapy... - New approaches to vaccine adjuvants: inhibiting the inhibitorBarney S Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
PLoS Med 3:e57. 2006 - Pathogenesis of respiratory syncytial virus infection in the murine modelR Stokes Peebles
Vaccine Research Center, NIAID NIH, 40 Convent Drive, Building 40, Room 2502, Bethesda, MD 20892 3017, USA
Proc Am Thorac Soc 2:110-5. 2005..This article briefly reviews the clinical sequelae of RSV infection and then focuses on the mechanisms of viral pathogenesis... - IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challengeTeresa R Johnson
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive MSC 3017, Building 40, Bethesda, MD 20892, USA
J Immunol 170:2037-45. 2003.... - Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in miceR S Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-2582, USA
J Med Virol 63:178-88. 2001.... - Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vectorAndrew T Catanzaro
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
J Infect Dis 194:1638-49. 2006..This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine... - Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challengesR S Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
J Infect Dis 184:1374-9. 2001..These data provide evidence that RSV-associated AHR occurs in hosts with allergic responses and that allergic inflammation is diminished when preceded by RSV infection... - Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengeT R Johnson
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
J Virol 72:2871-80. 1998..The ability of RSV to secrete G protein may therefore represent a viral strategy for immunomodulation and be a key determinant of disease pathogenesis... - Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSVR S Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
J Infect Dis 182:671-7. 2000..This study suggests that immune modulation with RSV vaccination can have profound effects on RSV-induced airway disease and that prevention of airway hyperresponsiveness is an important end point in vaccine development... - Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham
Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
J Infect Dis 177:310-9. 1998..Laboratory analysis suggested that vaccine-induced immune responses did not significantly affect the genotypic or phenotypic characteristics of transmitted virus or the early clinical course of HIV-1 infection... - Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivoS Aung
Department of Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
J Virol 73:8944-9. 1999..These results demonstrate that local expression of IL-4, at the time of antigen presentation, diminishes the cytolytic activity of primary and memory CD8(+) RSV-specific CTL responses in vivo... - Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccineAndrew T Catanzaro
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
Vaccine 25:4085-92. 2007..Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation... - Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesRichard A Koup
Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS ONE 5:e9015. 2010..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies... - Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann
Johns Hopkins University School of Public Health, Baltimore, Maryland, USA
J Infect Dis 177:1230-46. 1998..Trials with ALVAC expressing additional HIV components and rgp120 are underway... - Immune-mediated disease pathogenesis in respiratory syncytial virus infectionB S Graham
Department of Medicine, A 4103 MCN, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232 2582, USA
Immunopharmacology 48:237-47. 2000..This model suggests strategies for the development of new vaccine and immunotherapeutic interventions, and creates a framework for asking additional questions about the immunopathogenesis of RSV... - A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurateM Chen
Viral Pathogenesis Laboratory and Clinical Trials Core, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, 40 Convent Drive, Bethesda, MD 20892, United States
J Immunol Methods 362:180-4. 2010..Here, we describe a flow cytometry-based RSV-specific neutralization assay which is more rapid than traditional methods, highly sensitive and highly reproducible... - Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infectionTeresa R Johnson
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
Pediatr Infect Dis J 23:S46-57. 2004..Thus gene delivery by vector, by DNA or by live attenuated virus are attractive vaccine approaches... - Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine modelJie Liu
Vaccine Research Center, NIAID, National Institutes of Health, 40 Convent Dr, Bethesda, MD 20892 3017, USA
J Virol 83:4934-41. 2009..Characterization of epitope-specific CD4 T cells by novel fluorochrome-conjugated peptide-I-A(b) tetramers allows detailed analysis of their roles in RSV pathogenesis and immunity... - Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjectsJorge A Tavel
Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Acquir Immune Defic Syndr 44:601-5. 2007..To evaluate the safety and immunogenicity of a candidate HIV DNA vaccine administered using a needle-free device... - Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccinesS H Pincus
Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA
J Immunol 158:3511-20. 1997..These studies represent one of the most detailed analyses of the human Ab response to any Ag and have implications for the development of vaccines for HIV as well as for other microbial pathogens... - Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokineT R Johnson
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
J Gen Virol 82:2107-16. 2001..This suggests that the co-expression of cytokines and other immunomodulators has the potential to improve the safety of vaccine vectors while improving the immunogenicity of vaccine antigens... - Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virusJohn A Rutigliano
Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 2502, 40 Convent Drive, MSC 3017, Bethesda, MD 20892-3017, USA
Virology 337:335-43. 2005..Furthermore, identification of this H-2b-restricted CTL epitope provides access to genetically modified H-2b mice for more detailed studies of CTL mechanisms in RSV infection... - A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialJulie E Martin
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
Vaccine 26:6338-43. 2008..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study... - Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infectionJ E Fischer
Department of Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2582, USA
J Infect Dis 182:1029-38. 2000..These data confirm that the preexisting immune environment can change virus-specific immunity and provide both a model for study of RSV disease and evidence that noninfectious immunomodulators may impact pathogen-specific immunity... - Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitroT L Gower
Department of Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Antimicrob Agents Chemother 45:1231-7. 2001.... - Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infectionJohn A Rutigliano
Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 2502, 40 Convent Drive, MSC 3017, Bethesda, MD 20892 3017, USA
Virology 362:314-9. 2007..The hybrid mouse model provides a system to define rules of epitope hierarchy and better understand how antigen presentation and epitope competition affect the phenotype of effector and memory T cells... - Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infectionJohn A Rutigliano
Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 78:3014-23. 2004..These results may prove useful in the development of new therapies to combat RSV infection or other inflammatory diseases... - Structural basis of respiratory syncytial virus neutralization by motavizumabJason S McLellan
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Nat Struct Mol Biol 17:248-50. 2010..Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure... - Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced diseaseS Aung
Department of Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
J Virol 75:9918-24. 2001..We conclude that while perforin is not necessary for the clearance of primary RSV infection, the use of alternative CTL target cell killing mechanisms is less efficient and can lead to enhanced disease... - RhoA is activated during respiratory syncytial virus infectionT L Gower
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Virology 283:188-96. 2001..These observations indicate that RhoA and subsequent downstream signaling events are activated during RSV infection, which has implications for RSV pathogenesis... - Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitorK Hashimoto
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-2582, USA
Thorax 57:524-7. 2002.... - Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodiesSurender Khurana
Division of Viral Products, Center for Biologics Evaluation and Research (CBER, FDA, Bethesda, MD 20892, USA
J Virol 80:2092-9. 2006..The new HIV-SELECTEST is a simple but robust diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide... - Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virusTeresa R Johnson
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, United States of America
PLoS ONE 6:e16458. 2011..Defining the influence of RSV on the function of selected DC subsets may improve the likelihood of achieving protective vaccine-induced immunity... - A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialJulie E Martin
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
Clin Vaccine Immunol 13:1267-77. 2006.... - Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101FJason S McLellan
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 84:12236-44. 2010..Collectively, these results provide a structural basis for RSV neutralization by antibodies that target a major antigenic site on the fusion glycoprotein... - TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severityTeresa R Johnson
Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
Vaccine 27:3045-52. 2009..Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection... - Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responsesMelissa L Precopio
Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Exp Med 204:1405-16. 2007..This quality of the CD8(+) T cell response may be at least partially responsible for the profound efficacy of these vaccines in protection against smallpox and serves as a benchmark against which other vaccines can be evaluated... - Viral and host factors in human respiratory syncytial virus pathogenesisPeter L Collins
NIAID, NIH, 50 South Drive, MSC 8007, Bethesda, MD 20892, USA
J Virol 82:2040-55. 2008 - Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationCheng Cheng
Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
J Virol 84:630-8. 2010..These results have implications for future AIDS vaccine trials and the design of next-generation gene-based vaccine vectors... - Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoproteinTeresa R Johnson
Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892 3017, USA
J Leukoc Biol 84:748-59. 2008..These findings have important implications for the evaluation of candidate RSV vaccines... 
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal ruleNancy J Sullivan
Biodefense Research Section, Bethesda, Maryland 20892, USA
Nat Rev Microbiol 7:393-400. 2009..This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule...- Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparitiesTracy J Ruckwardt
Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 83:3019-28. 2009.... - Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trialsRichard A Koup
Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
J Virol 83:6318-22. 2009..These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells... - Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccineBarney S Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
J Infect Dis 194:1650-60. 2006..Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine... - Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVTeresa R Johnson
Vaccine Research Center, NIAID, NIH, Bldg 40, Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
J Virol 78:8753-60. 2004.... - Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infectionJohn A Rutigliano
Vaccine Research Center National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 173:3408-17. 2004..In addition, the revelation that TNF-alpha is the principal mediator of RSV-induced illness means that administration of TNF receptor antagonists, in combination with antiviral therapy, may be an effective method to treat RSV infections... - Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSVTeresa R Johnson
VRC, NIAID, NIH, Bldg 40 Room 2614, 40 Convent Dr, MSC 3017, Bethesda, MD 20892 3017, USA
J Virol 78:6024-32. 2004.... - Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humansJ E Ledgerwood
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Clin Vaccine Immunol 19:1792-7. 2012..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens... - Immunological determinants of disease caused by respiratory syncytial virusB S Graham
Dept of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 2605, USA
Trends Microbiol 4:290-3. 1996..Vaccination can influence the types of cytokine produced by selectively activating T cell subpopulations and inducing an immune response that clears the virus with minimal immunopathology... - A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trialJulie E Martin
Vaccine Research Center, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
J Infect Dis 196:1732-40. 2007..West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study... - Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4Lewis H McCurdy
Vaccine Research Center/NIAID/NIH, 40 Convent Drive, MSC 3017, Building 40, Room 2502, Bethesda, MD 20892-3017, USA
J Virol 78:12471-9. 2004..These data support the continued development of MVA as an alternative candidate vaccine for smallpox... - Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralizationSteevenson Nelson
Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS Pathog 4:e1000060. 2008..Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV... - Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individualsJanie Parrino
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Vaccine 25:1513-25. 2007..MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses... - Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypesSurender Khurana
Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
J Acquir Immune Defic Syndr 43:304-12. 2006..Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide... - Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitopeTracy J Ruckwardt
Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 185:4673-80. 2010..These data demonstrate efficient viral clearance, and a protective effect of subdominant CD8(+) T cell responses... - RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphologyTara L Gower
Vaccine Research Center, Building 40, Room 2502, NIAID, NIH, 40 Convent Dr, MSC 3017, Bethesda, MD 20892-3017, USA
J Virol 79:5326-36. 2005..These data suggest that viral filamentous protuberances characteristic of RSV infection are associated with RhoA signaling, are important for filamentous virion morphology, and may play a role in initiating cell-to-cell fusion... - A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsJ E Ledgerwood
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
Vaccine 29:304-13. 2010..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses... - Subunit recombinant vaccine protects against monkeypoxJean-Michel Heraud
Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA
J Immunol 177:2552-64. 2006..Their identification may guide future efforts to develop simpler, safer, and more effective vaccines for monkeypox and smallpox... - Modified vaccinia Ankara: potential as an alternative smallpox vaccineLewis H McCurdy
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3017, USA
Clin Infect Dis 38:1749-53. 2004..Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine... - Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United StatesSylvain Cecchini
Laboratory of Biochemical Genetics, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Vaccine Immunol 16:597-604. 2009..Using ELISA, we tested 404 human serum samples and established a range of antibody titers in a large U.S. adult population sample... - A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virionsWei Shi
Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, Rm 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
J Virol 82:6190-9. 2008..The acidic character of this domain is likely responsible for its aberrant biochemical properties. These findings demonstrate that this region is essential for the assembly of the filamentous nucleocapsids that give rise to filoviruses... - Smallpox vaccines: Past, present, and futureJanie Parrino
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
J Allergy Clin Immunol 118:1320-6. 2006.... - Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levelsKoichi Hashimoto
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-2650, USA
J Allergy Clin Immunol 116:550-7. 2005..CONCLUSION: These results show that STAT 1 has an important regulatory role in RSV-induced alteration of airway function... - The complex relationship between respiratory syncytial virus and allergy in lung diseaseR Stokes Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Viral Immunol 16:25-34. 2003..We also review the published murine models that combine RSV infection and allergic sensitization that attempt to explain the complex relationship between these two factors in regard to lung immunopathology and physiologic dysfunction... - Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependentR Stokes Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
J Immunol 175:8253-9. 2005..These results elucidate the pathways by which COX inhibition exerts a critical effect of the pulmonary allergen-induced inflammatory response and confirm that COX products are important regulators of allergic inflammation... - The role of IFN in respiratory syncytial virus pathogenesisJoan E Durbin
Children s Research Institute, Children s Hospital, Columbus, OH 43205, USA
J Immunol 168:2944-52. 2002..These findings suggest that STAT1 activation by both type I (alphabeta) and type II (gamma) IFNs plays an important role in establishing a protective, Th1 Ag-specific immune response to RSV infection... - Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virusPeter F Wright
Departments of Pediatrics, Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232 2581, USA
J Infect Dis 185:1011-8. 2002..The response was not influenced by age, primary diagnosis, amount of virus recovered, or severity of illness but was suppressed by preexisting antibody... - Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in miceR Stokes Peebles
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Am J Respir Crit Care Med 165:1154-60. 2002..We conclude that in the BALB/c mouse, COX inhibition with either a COX-1 or COX-2 inhibitor during allergen sensitization augments production of IL-13 and increases airway hyperresponsiveness... - Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Acquir Immune Defic Syndr 44:203-12. 2007..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy... - NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virusTeresa R Johnson
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
J Virol 76:4294-303. 2002..These findings indicate that CD1d-dependent NK T cells play a role in expansion of CD8(+) T cells and amplification of antiviral responses to RSV... - RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV GPhilip J Budge
Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
J Virol 78:5015-22. 2004.... - Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illnessKoichi Hashimoto
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
J Virol 78:10303-9. 2004..These results suggest that signaling through IP has antiviral effects while protecting against RSV-induced illness and that PGI(2) is a potential therapeutic target in the treatment of RSV... - Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5Koichi Hashimoto
Vanderbilt University, School of Medicine, Nashville, Tennessee 37232, USA
Am J Respir Crit Care Med 170:306-12. 2004..The impact of virus infection combined with allergic inflammation on mucus production may partially explain the more severe disease and airway hyperresponsiveness associated with RSV in the setting of atopy... - The histopathology of fatal untreated human respiratory syncytial virus infectionJoyce E Johnson
Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA
Mod Pathol 20:108-19. 2007..These findings inform our understanding of RSV pathogenesis and may facilitate the development of new approaches for prevention and treatment... - Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding virusesPhilip J Budge
Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
J Antimicrob Chemother 54:299-302. 2004.... - Lessons from failure--preparing for future HIV-1 vaccine efficacy trialsBarney S Graham
J Infect Dis 191:647-9. 2005 - Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 190:903-7. 2004..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection... - Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanismsKoichi Hashimoto
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
J Immunol 174:525-32. 2005..These results illustrate the central role played by products derived from the COX pathway in the regulation of allergic immune responses... - Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy UgandansMichael A Eller
Makerere University Walter Reed Project, Kampala, Uganda
Vaccine 25:7737-42. 2007.... - IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouseWeisong Zhou
Department of Medicine, T-1218 MCN, Vanderbilt University Medical Center, Nashville, TN 37232-2650, USA
Microbes Infect 8:2880-9. 2006..These results suggest that IL-13 modulates illness from RSV-infection... - Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003Alexander C Schmidt
Department of Pediatric Pulmonology and Immunology, Charite University Hospital, Berlin, Germany
Virus Res 106:1-13. 2004..Chanock Award for lifetime achievement in RSV research, an award named in honor of the person who started the field of RSV research by recovering the first human RS virus from infants with severe bronchiolitis in 1956... - Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimersPhilip J Budge
Department of Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Antimicrob Agents Chemother 47:3470-7. 2003.... - Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathwaysChun Geun Lee
Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8057, USA
J Biol Chem 277:35466-74. 2002..These responses are mediated by multiple mechanisms with mucus metaplasia being dependent on and the inflammation and fibrosis being independent of an IL-13/IL-4R(alpha)/STAT-6 activation pathway... - Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosisYi Wei Tang
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
J Clin Microbiol 41:2633-40. 2003..05). Immunohistochemistry for EBV or HHV-8 antigen showed viral antigen primarily in airway epithelial cells. These data support the concept that a herpesvirus could be a source of chronic antigenic stimulation in IPF...